Document is current
Any future updates will be listed below
-
Authors
Manni, Simona https://orcid.org/0000-0003-1845-6674
Del Bufalo, Francesca https://orcid.org/0000-0001-9643-3465
Merli, Pietro
Silvestris, Domenico Alessandro
Guercio, Marika
Caruso, Simona
Reddel, Sofia
Iaffaldano, Laura
Pezzella, Michele https://orcid.org/0000-0003-0088-7695
Di Cecca, Stefano
Sinibaldi, Matilde
Ottaviani, Alessio https://orcid.org/0000-0002-4796-3184
Quadraccia, Maria Cecilia https://orcid.org/0000-0002-4877-2793
Aurigemma, Mariasole https://orcid.org/0000-0003-2804-8770
Sarcinelli, Andrea https://orcid.org/0000-0002-8628-3878
Ciccone, Roselia
Abbaszadeh, Zeinab
Ceccarelli, Manuela https://orcid.org/0000-0001-8741-1600
De Vito, Rita
Lodi, Maria Chiara
Cefalo, Maria Giuseppina
Mastronuzzi, Angela https://orcid.org/0000-0002-4408-2373
De Angelis, Biagio https://orcid.org/0000-0002-7938-737X
Locatelli, Franco https://orcid.org/0000-0002-7976-3654
Quintarelli, Concetta
-
Funding
Funding for this research was provided by:
Ministero della Salute (RF-2021-12374120, GR-2016-02364546)
Associazione Italiana per la Ricerca sul Cancro (MFAG 21979, Special Project 5×1000 no. 9962 (F.L.))
- License Information
-
More Information
Article History
Received: 23 March 2022
Accepted: 10 May 2023
First Online: 9 June 2023
Competing interests
: F.L. and P.M. declare the following competing interests: on September 2022 participated in an advisory board on primary HLH organized by Sobi, receiving honoraria. All the other authors do not have any competing interests to disclose. SOBI has not supported the study, besides the provision of the emapalumab drug.
